Pancreatic Cancer Research

ResearcherPhilipps University of MarburgNo recent work listed

Eike Gallmeier

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5037392449. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 11

  1. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  2. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life resu… Co-author DOI 10.1002/ijc.33336↗
  3. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  4. [Pancreatic ductal adenocarcinoma]. Co-author DOI 10.1007/s00108-018-0460-z↗
  5. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  6. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Co-author DOI 10.1016/j.thromres.2017.06.021↗
  7. Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis. Last author DOI 10.1111/jcmm.12444↗
  8. Controversy on the time to progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2014-309066↗
  9. ALK expression is absent in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-014-1774-4↗
  10. Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. Co-author DOI 10.1371/journal.pone.0056760↗
  11. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. Last author DOI 10.1111/j.1582-4934.2011.01473.x↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Mathias Gress · 2 shared papers, 2015–2018 · strength 0.26
  2. Andrea Tannapfel · 3 shared papers, 2018–2023 · strength 0.25
  3. Thomas Jens Ettrich · 3 shared papers, 2018–2023 · strength 0.25
  4. Waldemar H. Uhl · 3 shared papers, 2018–2023 · strength 0.25
  5. Michael Geißler · 3 shared papers, 2018–2023 · strength 0.25
  6. Thomas Theodor Werner Seufferlein · 3 shared papers, 2018–2023 · strength 0.25
  7. Anke Reinacher‐Schick · 3 shared papers, 2018–2023 · strength 0.25
  8. Alexander Otto König · 3 shared papers, 2018–2023 · strength 0.25
  9. Hana Algül · 3 shared papers, 2018–2023 · strength 0.25
  10. Marko Kornmann · 3 shared papers, 2018–2023 · strength 0.25
  11. Michael B. Ghadimi · 2 shared papers, 2019–2023 · strength 0.19
  12. Detlef Klaus Bartsch · 2 shared papers, 2019–2023 · strength 0.19
  13. Alexander Kleger · 2 shared papers, 2019–2023 · strength 0.19
  14. Helmut Friess · 2 shared papers, 2019–2023 · strength 0.19
  15. S Daum · 2 shared papers, 2018–2023 · strength 0.18
  16. Uwe A. Wittel · 2 shared papers, 2018–2023 · strength 0.18
  17. Lukas Perkhofer · 2 shared papers, 2018–2023 · strength 0.18
  18. Christiane J. Bruns · 3 shared papers, 2012–2023 · strength 0.18
  19. Andreas Wolfgang Berger · 2 shared papers, 2018–2019 · strength 0.14
  20. Jasmin Schuhbaur · 1 shared paper, 2023 · strength 0.12
  21. Volker Kunzmann · 1 shared paper, 2023 · strength 0.12
  22. Ingo Klein · 1 shared paper, 2023 · strength 0.12
  23. Manfred Paul Lutz · 1 shared paper, 2023 · strength 0.12
  24. Angelika M. R. Kestler · 1 shared paper, 2023 · strength 0.12
  25. Margaret A. Tempero · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.